OBRAVNAVA BOLNIKOV Z AKUTNIM KORONARNIM SINDROMOM: STROKOVNA IZHODIŠČA ZA OBRAVNAVO V LJUBLJANSKI REGIJI
Povzetek
–Prenosi
Literatura
Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J 1995; 16: Suppl L: 3–7.
McCarthy B, Wong J, Selker H. Detecting acute ischemia in the emergency department. J Gen Int Med 1990; 5: 365–73.
WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Circulation 1994; 90: 583–612.
The Pursuit trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–43.
Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333–41.
European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–32.
ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on the management of patients with unstable angina). Circulation 2000; 102: 1193–209.
European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 1996; 17: 43–63.
ACC/AHA. 1999 Update: ACC/AHA Guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on management of acute myocardial infarction). Circulation 1999; 100: 1016–30.
European Society of Cardiology. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. The Joint European Society of Cardiology/American College of Cardiology Committee. Eur Heart J 2000; 21: 1502–13.
Brener SJ, Bar LA, Burchenal JEB, Katz S et al. on behalf of the ReoPro and Primary PTCA organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734–41.
O’Shea C, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. J Invas Cardiol 1999; 11: 494–9.
van den Merkhof LF, Zijlstra F, Olsson H, Grip L et al. Abciximab in the treatment of acute MI eligible for primary percutaneous transluminal coronary angioplasty. Results of the GP Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33: 1528–32.
Topol EJ, Moliterno DJ, Hermann HC, Powers ER et al. for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–94.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61.
The Fibrinolytic Therapy Trialists. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B Med J 1994; 308: 81–95.
CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996; 348: 1329– 39.
ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57–66.
Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto miocardico. GISSI-3: Effects of lisinopril and transdermal nitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22.
ISIS-4 Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58,000 patients with suspected acute myocardial infarction. Lancet 1994; 345: 669–85.
Hamm CW, Ravkilde J, Gerhardt W. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–50.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to Aspirin in Pts with acute coronary syndromes without ST-segment elevation. N Engl J Med 345; 494– 502.
The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–35.
The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–53.
The PARAGON investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: 2386–95.
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97.
The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in pts with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–24.
Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave MI. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–8.
Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–7.
FRAXIS study group. Comparison of two treatment durations of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. Eur Heart J 1999; 20: 1553–62.
TIMI-IIIb Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-ST elevation myocardial infarction: results of the TIMI IIIb trial. Circulation 1994; 89: 1545–56.
Boden WE, O’Rourke RA, Crawford MH. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared to a conservative management strategy. N Engl J Med 1998; 338: 1785–92.
Cannon CP, Weintraub WS, Demopoulos, Vicari R et al. for the TACTICSThrombolysis In MI 18 Investigators. Comparison of early invasive and conservative strategies in pts with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87.
The EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92.
Prenosi
Številka
Rubrika
Licenca
Avtor na prispevku, ki ga bo pripravil za Zdravniški vestnik, po pogodbi nanj prenaša vse materialne avtorske pravice, kakor izhajajo iz 22. člena Zakona o avtorski in sorodnih pravicah, in sicer pravico reproduciranja, pravico javnega izvajanja, pravico javnega prenašanja, pravico javnega predvajanja s fonogrami in videogrami, pravico javnega prikazovanja, pravico radiodifuznega oddajanja, pravico radiodifuzne retransmisije, pravico sekundarnega radiodifuznega oddajanja, pravico dajanja na voljo javnosti, pravico predelave, pravico avdiovizualne priredbe, pravico distribuiranja ter pravico dajanja v najem in vse druge pravice avtorja v skladu z ZASP.
Avtorjev prenos pravic po pogodbi je neizključen, velja za neomejeno število izdaj, za ves čas trajanja materialnih avtorskih pravic ter je prostorsko neomejen.
Avtor sme avtorsko delo tudi sam izkoriščati ali avtorske pravice prenašati na tretje osebe, vendar oboje šele po preteku 3 mesecev od prve objave dela v reviji Zdravniški vestnik.
Avtor Zdravniškemu vestniku izrecno dovoli, da lahko pravice, pridobljene v skladu s pogodbo prenaša naprej na tretje osebe brez omejitev.
Avtor se strinja, da Zdravniški vestnik prispevek objavi pod pogoji licence Creative Commons BY-NC 4.0 (navedba avtorstva-nekomercialno) ali primerljive licence.
